BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
| Revenue (TTM) | $940.61M |
| Gross Profit (TTM) | $727.92M |
| EBITDA | $433.05M |
| Operating Margin | 45.10% |
| Return on Equity | -1925.00% |
| Return on Assets | 52.90% |
| Revenue/Share (TTM) | $4.10 |
| Book Value | $-1.78 |
| Price-to-Book | 56.59 |
| Price-to-Sales (TTM) | 2.33 |
| EV/Revenue | 2.792 |
| EV/EBITDA | 7.17 |
| Quarterly Earnings Growth (YoY) | 1400.00% |
| Quarterly Revenue Growth (YoY) | 33.60% |
| Shares Outstanding | $255.53M |
| Float | $222.32M |
| % Insiders | 1.28% |
| % Institutions | 105.34% |
Volatility is currently contracting
After its most recent pullback, biopharmaceutical stock BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) bounced off the $8 level and has now reclaimed the 320-day moving average -- both of which have been key lines of pressure and support.
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June.
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.
Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE patients, leveraging existing commercial infrastructure for operating leverage and customer retention.
The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly stepping in to develop and acquire rare disease drugs.
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BCRX and any ticker you trade — then tracks every position and per-strategy win rate.
